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Abstract Although several studies have evaluated the effect of
synbiotic intake on metabolic profiles in patients with diabetes,
findings are inconsistent. This systematic review and meta-
analysis of randomized controlled trials (RCTs) was conducted
to summarize the evidence on the effect of synbiotic intake on
metabolic profiles in patients with diabetes. The PubMed,
EMBASE, Web of Science, and Cochrane Library databases
were systematically searched. All RCTs published up to 12
November 2016 were included. Two review authors indepen-
dently assessed study eligibility, extracted data, and evaluated
risk of bias of included studies. Heterogeneity was measured
with a Q test and with I2 statistics. Data were pooled by using
the fix or random-effect model based on the heterogeneity test
results and expressed as standardized mean difference (SMD)
with 95% confidence interval (CI). A total of seven randomized
controlled trials were included. Synbiotic consumption signifi-
cantly changed glucose metabolism, including fasting plasma
glucose (FPG) (SMD = −0.29; 95% CI, −0.47, −0.10), insulin
concentrations (SMD = −0.84; 95% CI, −1.61, −0.06), homeo-
stasis model assessment of insulin resistance (HOMA-IR)
(SMD = −0.80; 95% CI, −1.58, −0.03), homeostatic model
assessment-B cell function (HOMA-B) (SMD = −0.36; 95%
CI, −0.71, −0.01), quantitative insulin sensitivity check index
(QUICKI) (SMD = 0.46; 95% CI, 0.09, 0.82), and significantly
improved lipid profiles, such as triglycerides (SMD = −0.36;
95% CI, −0.55, −0.17), very low density lipoprotein-cholesterol
(SMD = −0.31; 95% CI, −0.55, −0.08), and total cholesterol
(SMD = −0.32; 95% CI, −0.67, −0.03), but had no effect on
low density lipoprotein-cholesterol (SMD = −0.07; 95% CI,
−0.58, 0.43) and high density lipoprotein-cholesterol concentra-
tions (SMD = −0.25; 95% CI, −0.81, 0.31). Synbiotic may result
in an improvement in FPG, insulin, HOMA-IR, HOMA-B,
QUICKI, triglycerides, and total cholesterol.
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Introduction
Impaired glucose metabolism, insulin resistance, and dyslip-
idemia are causally related to a greater risk of several chronic
disorders, including diabetes, obesity, fatty liver, and cardio-
vascular diseases (CVDs) [1]. Blood glucose and lipid profiles
can be controlled by proper eating pattern to prevent or control
diabetes or related disorders [2]. In addition, existing evidence
suggests that supplements such as omega-3 fatty acids [3],
vitamin D [4], and dairy products [5] can improve glycemic
control and lipid profiles or reduce risk of diabetes and CVD.
Probiotic and synbiotic are suggested to manage metabolic
profiles of patients suffering from diseases related to metabolic
syndrome. Synbiotics refer to nutritional supplements that are
combining probiotics and prebiotics in a form of synergism [6].
Few studies have evaluated the effects of synbiotic-containing
products on glucose metabolism and lipid profiles among pa-
tients with type 2 diabetes mellitus (T2DM) [7] and pregnant
women [8]; however, findings were inconsistent. Such
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controversial findings complicate approaches to and conclusions
about synbiotic use. In a meta-analysis by Beserra et al. [9],
synbiotic supplementation among overweight or obese adults
resulted in reductions in plasma fasting insulin and triglyceride
fractions, while prebiotic supplementation resulted in reduction
of triglycerides, plasma total cholesterol, and low density lipo-
protein (LDL)-cholesterol levels and increased high density lipo-
protein (HDL)-cholesterol level. In another study by Ruan et al.
[10], reduced fasting glucose, insulin concentrations, and homeo-
stasis model assessment of insulin resistance (HOMA-IR) were
observed among percipients who consumed probiotic supple-
ment compared with controls. Synbiotics are being used to mod-
ulate gut microbiota with favorable benefits for glucose homeo-
stasis parameters and lipid profiles through mechanisms such as
the production of short-chain fatty acid (SCFA), carbon disulfide,
and methyl acetate [11] and decreased expression of
inflammation-relevant genes [12], energy harvest, storage and
expenditure from diet, satiety hormone balance, regulation of
lipid synthesis, and improvement of markers of insulin metabo-
lism and modulating the immune function [13].
Numerous randomized controlled trials (RCTs) have been
conducted to determine whether synbiotic supplementation
has a causal effect on glucose metabolism and lipid profiles.
This study aimed to systematically review the current evi-
dence on the effect of synbiotic supplementation on glucose
metabolism and lipid profiles in RCTs among patients with
diabetes and to summarize the available findings in a meta-
analysis, if possible.
Methods
Search Strategy
Relevant studies were systematically searched from online
databases PubMed, EMBASE, Web of Science, and
Cochrane Library databases up to 12 November 2016. The
search was conducted based on PICOS elements (Table 1).
Search terms included patients [Bdiabetes^ OR BT2DM^ OR
Bgestational diabetes mellitus (GDM)^], intervention
(Bsynbiotic^ OR Bsymbiotic^ AND Bsupplementation^ OR
Bintake^), and outcomes [Bfasting plasma glucose (FPG)^
OR Binsulin^OR Bhomeostatic model assessment-B cell func-
tion (HOMA-B)^ OR Bhomeostatic model assessment-B cell
function (HOMA-B)^ OR Btotal-cholesterol^ OR Btriglycer-
ides^ ORBLDL-cholesterol^ OR BHDL-cholesterol^ OR
BVLDL-cholesterol^ OR Bquantitative insulin sensitivity
check index (QUICKI)^]. Search was conducted by two inde-
pendent researchers. References cited in the selected studies
were manually searched for additional relevant articles.
Additionally, the relevant research centers and experts of the
field were contacted to find unpublished studies. Our search
was restricted to studies published in the English language.
Selection Criteria
The eligibility criteria were human RCTs, patients with T2DM
or GDM, and administration of synbiotic or symbiotic supple-
ments. Studies that did not reported mean changes of glucose
metabolism and lipid profiles, along with standard deviation
(SD) for the intervention and control groups, the abstracts of
seminars without full text, case reports, and studies that did
not obtain the minimum required score of quality assessment
process were excluded.
Quality Assessment
Data extraction and study quality assessment were conducted
by two independent reviewers (ZA and MA), according to
Cochrane Collaboration risk of bias tool. The scale includes
three domains related to quality of clinical trials: (1) random
sequence generation description (0 = no description, 1 = inad-
equate description, 2 = adequate description), (2) blinding
process (2 = double blinding with adequate description,
1 = double blinding with inadequate description, 0 = wrong
usage of double blinding), and (3) withdrawal of patients
(1 = the number and reasons of patients withdrawal described,
0 = otherwise). In the event of disagreement, resolved by
discussion until consensus was reached.
Statistical Methods
RevMan software (Cochrane ReviewManager, version 5.2) and
STATA version 12.0 (Stata Corp., College Station, TX) were
used for data analyses. Heterogeneity was evaluated through
the Cochran (Q) and I-squared tests (I2). Given the existing het-
erogeneity between studies, when I2 exceeds 50% or P < 0.05,
the random-effect model was used; otherwise, the fixed-effect
Table 1 PICOS criteria used to define the research question for the
systematic review criteria description
Population Adult populations (aged >18 years) with diabetes [type 2
diabetes mellitus (T2DM) and gestational diabetes
mellitus (GDM)]
Interventions Synbiotic capsules/synbiotic food
Comparison
group
Placebo capsules/placebo food
Outcomes Glucose metabolism including fasting plasma glucose
(FPG), insulin concentrations, homeostasis model
assessment of insulin resistance (HOMA-IR),
homeostatic model assessment-B cell function
(HOMA-B), quantitative insulin sensitivity check
index (QUICKI), and lipid profiles such as
triglycerides, VLDL-cholesterol, total cholesterol,
LDL-cholesterol, and HDL-cholesterol
concentrations) at baseline and at the end of the
intervention
Study design All randomized controlled trials
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model was applied. Inverse variancemethod andCohen statistics
were used for estimation of standardizedmean difference (SMD)
and 95% CI for verifying the outcome behavior of each study
group (intervention/control). Sensitivity analyses also undertook
in the trials one by one to evaluate the reliability of the pooled
mean difference. In addition, the Cochrane Collaboration risk of
bias tool was used to assess the methodological quality of the
RCTs. Potential publication bias was assessed through visual
inspection of funnel plots and quantitatively assessed using
Egger’s tests.
Results
Search Results and Trial Flow
A total of 1328 studies were identified through the database
search. Of these, 302 duplicate articles, 261 not randomized
controlled trials, and 4 review articles were excluded. After
reading titles and abstracts, 761 articles were excluded and 23
full text articles were assessed for eligibility. One article was
included form the references cited in the selected studies. The
remaining 23 articles were retrieved for further review, and 9
were deemed relevant. Of these, we excluded 14 articles that
examined non-diabetic patients (n = 3), did not presented re-
quired data for meta-analyses (n = 11), and did not adminis-
trated symbiotic (n = 2). Finally, seven studies were found to
be appropriate for in this meta-analysis [8, 14–19] (Fig. 1).
Characteristics of Included Studies
Totally, seven studies with 482 participants were included in
the final meta-analysis. Six studies were double blind, and one
study was single blind [17]. Four studies used parallel design,
and two used crossover design [15, 16]. The intervention du-
ration varied from 6 to 12weeks. Six studies have investigated
the effects of synbiotic supplementation on glucose metabo-
lism and lipid profiles in patients with T2DM and one study in
patients with GDM [14]. Six studies have reported changes in
FPG, triglycerides, total cholesterol, and HDL-cholesterol,
and five studies have reported changes in insulin concentra-
tions, HOMA-IR, and LDL-cholesterol, and four studies have
reported changes inHOMA-B, QUICKI, and very low density
lipoprotein (VLDL)-cholesterol levels. The synbiotic species
and used dosage were varied between studies. Five studies
have used combination of more than two strains, whereas
two studies have used a single species of probiotics [15, 16].
Total daily dose of probiotic intake was varied from 106
colony-forming units (CFU) to 108 CFU, except for one study
that has used 1500 mg probiotic capsule twice daily.
Participants of three studies in the intervention group con-
sumed synbiotic capsules, and those in the control group con-
sumed placebo capsules. Participants of four studies in the
intervention group consumed synbiotic food, and those in
the control group consumed control food. The characteristics
of included studies are presented in Table 2. The methodolog-
ical quality based on authors’ judgments about each risk of
bias item for each included study is shown in Fig. 2.
Pooled Effects of Synbiotic on Glucose Metabolism
Figure 3 shows the forest plots for effect of synbiotic on glu-
cose metabolism parameters. We observed that synbiotic con-
sumption significantly improved glucose metabolism, such as
FPG (SMD −0.29; 95% CI, −0.47, −0.10), insulin concentra-
tions (SMD = −0.84; 95% CI, −1.61, −0.06; I2 = 92.6%,
P < 0.001), HOMA-IR (SMD = −0.80; 95% CI, −1.58,
−0.03; I2 = 92.6%, P < 0.001), HOMA-B (SMD = −0.36;
95% CI, −0.71, −0.01; I2 = 53.0%, P = 0.094), and QUICKI
(SMD = 0.46; 95% CI, 0.09, 0.82; I2 = 55.7%, P = 0.08).
Evidence of inter-study heterogeneity was observed across
studies on glucose metabolism parameters; therefore, the
random-effect model was used. Sensitivity analysis was per-
formed by removing the trials one by one to evaluate the
reliability of the pooled standardize mean difference; expect
Articles screened by title and 
abstract (n=760) 
Articles identified through electronic database 
search (n=1328) 
Excluded non-relevant 
articles (n=737) 
Article excluded (n=568): 
-Duplicate articles (n=302) 
-Not randomized controlled trials (n=261) 
-Review (n=4) 
Not human (n=1) 
Full text articles assessed for 
eligibility (n=22) 
Articles identified through 
reference checking (n=1) 
Articles excluded (n=16) 
-Not diabetes population (11)  
-Data presentation inappropriate for meta-
analysis (n=3) 
No use of synbiotic (n=2) 
Studies included in this study 
(n=7) 
Fig. 1 Literature search and review flow chart for selection of studies
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Asemi et al. [15] study, results remained consistent after re-
moving the trials for insulin and HOMA-IR.
Pooled Effects of Synbiotic on Lipid Profiles
Similar results were observed for lipid profiles. The effect of
synbiotic supplementation on triglycerides and VLDL-
cholesterol levels was examined in seven RCTs; significant
decrease in SMD −0.32 (95% CI, −0.67, −0.03), −0.36
(95% CI, −0.55, −0.17), and −0.31 (95% CI, −0.55, −0.08)
was observed between intervention and placebo groups for
any of the lipid profiles, respectively (Table 3). Due to hetero-
geneity of studies, the results of total cholesterol studies were
combined by using random-effect model (I2 = 66.4%,
P = 0.011). Synbiotic consumption significantly decreased
triglycerides (SMD = −0.36; 95% CI, −0.55, −0.17), VLDL-
cholesterol (SMD = −0.31; 95% CI, −0.55, −0.08), and total
cholesterol (SMD = −0.32; 95% CI, −0.67, −0.03), but had no
significant effect on LDL-cholesterol (SMD = −0.07; 95% CI,
−0.58, 0.43) and HDL-cholesterol concentrations
(SMD = −0.25; 95% CI, −0.81, 0.31) (Fig. 4). Sensitivity
analysis showed that removing studies with high heterogene-
ity in lipid profiles did not change the pooled effect.
Meta-Regression and Subgroup Analyses
Subgroup analyses for all metabolic profiles were done based
on bacteria strain (Figs. 3 and 4). The univariate meta-
regression analyses based on bacteria strain, time of interven-
tion, and the number of bacteria did not show any statistically
significant subgroup-effect interactions on lipid profiles
(P ≥ 0.05 for all comparisons). However, among glucose me-
tabolism, parameters as FPG based on time of intervention
and insulin by bacteria strain and the number of bacteria had
statistically significant subgroup-effect interactions (P < 0.05)
(Table 4).
Table 2 Characteristics of included studies
Ref. Intervention/control (sample
size)
Duration
(weeks)
Age
(years)
Strain Dosage (CFU/
g)
Number of
bacteria
Ahmadi et al. [14] Synbiotic capsules/placebo
capsules (35/35)
<8 18–40 Lactobacillus acidophilus,
Lactobacillus casei, and
Bifidobacterium bifidum
2 × 109 >2
Asemi et al. [15] Synbiotic food/control food
(62/62)
<8 35–70 Lactobacillus sporogenes 1 × 07 ≤2
Asemi et al. [16] Synbiotic fortified/placebo
capsules (51/51)
<8 35–70 Lactobacillus sporogenes 1 × 107 ≤2
Moroti et al. [17] Symbiotic shake/placebo shake
(10/10)
<8 50–65 Lactobacillus acidophilus,
Bifidobacterium bifidum,
oligofructose
108 ≤2
Tajadadi-Ebrahimi
et al. [18]
Synbiotic bread/control bread
(27/27)
≥8 35–70 Lactobacillus sporogenes 1 × 108 ≤2
Shakeri et al. [8] Synbiotic bread/control bread
(26/26)
≥8 35–70 Lactobacillus sporogenes 1 × 108 ≤2
Tajadadi-Ebrahimi
et al. [19]
Synbiotic capsules/placebo
capsules (30/30)
≥8 40–85 Lactobacillus acidophilus,
Lactobacillus casei, and
Bifidobacterium bifidum
2 × 109 >2
Fig. 2 The methodological quality of included studies
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Publication Bias
The Egger’s regression was performed to detect potential pub-
lication bias. Egger’s regression indicated no significant pub-
lication bias for all indices (Β = 1.67, P = 0.605).
Discussion
To our knowledge, this is the first meta-analysis of RCTs that
examined the effect of synbiotic supplementation on glucose
metabolism and lipid profiles among patients with diabetes.
Heterogeneity between groups: p = 0.126
Overall (I-squared = 18.8%, p = 0.291)
synbiotic food
Subtotal (I-squared = 0.0%, p = 0.427)
Subtotal (I-squared = 3.4%, p = 0.309)
Shakeri (2014)
ID
synbiotic capsules
Asemi (2016)
ahmadi (2016)
Tajadadi-Ebrahimi (2014)
Study
Asemi (2014)
Tajadadi-Ebrahimi (2016)
-0.29 (-0.47, -0.10)
-0.38 (-0.59, -0.16)
-0.06 (-0.40, 0.29)
-0.62 (-1.17, -0.06)
SMD (95% CI)
-0.22 (-0.61, 0.17)
0.11 (-0.36, 0.58)
-0.68 (-1.23, -0.13)
-0.28 (-0.63, 0.07)
-0.25 (-0.76, 0.26)
100.00
71.50
28.50
10.91
Weight
22.32
15.40
11.22
%
27.04
13.11
  I i t
0-1.23 1.23
A
NOTE: Weights are from random effects analysis
Overall (I-squared = 92.6%, p = 0.000)
Asemi (2016)
Tajadadi-Ebrahimi (2014)
Study
Asemi (2014)
Subtotal (I-squared = 0.0%, p = 0.524)
synbiotic food
ahmadi (2016)
ID
Subtotal (I-squared = 96.1%, p = 0.000)
synbiotic capsules
Tajadadi-Ebrahimi (2016)
-0.84 (-1.61, -0.06)
-0.28 (-0.67, 0.11)
-0.38 (-0.92, 0.16)
-2.34 (-2.80, -1.89)
-0.59 (-0.94, -0.24)
-0.70 (-1.18, -0.22)
SMD (95% CI)
-1.00 (-2.34, 0.33)
-0.47 (-0.98, 0.04)
100.00
20.52
19.60
%
20.12
39.75
19.97
Weight
60.25
19.78
0-2.8 2.8
B
Fig. 3 a–eMeta-analysis glycemic parameters’ standardizedmean difference estimates for a FPG, b for insulin, c for HOMA-IR and dHOMA-B, and e
for QUICKI in synbiotic and placebo groups (CI = 95%)
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 92.6%, p = 0.000)
Asemi (2016)
Tajadadi-Ebrahimi (2014)
Study
Asemi (2014)
Subtotal (I-squared = 62.4%, p = 0.103)
synbiotic food
ahmadi (2016)
ID
Subtotal (I-squared = 95.5%, p = 0.000)
synbiotic capsules
Tajadadi-Ebrahimi (2016)
-0.80 (-1.58, -0.03)
-0.32 (-0.71, 0.07)
-0.55 (-1.10, -0.01)
-2.28 (-2.74, -1.83)
-0.43 (-1.00, 0.14)
-0.71 (-1.20, -0.23)
SMD (95% CI)
-1.05 (-2.31, 0.20)
-0.13 (-0.64, 0.38)
100.00
20.51
19.56
%
20.15
39.78
19.96
Weight
60.22
19.81
0-2.74 2.74
C
NOTE: Weights are from random effects analysis
Overall (I-squared = 53.0%, p = 0.094)
Subtotal (I-squared = 0.0%, p = 0.849)
ahmadi (2016)
Tajadadi-Ebrahimi (2014)
ID
synbiotic food
Asemi (2016)
Subtotal (I-squared = 0.0%, p = 0.339)
synbiotic capsules
Tajadadi-Ebrahimi (2016)
Study
-0.36 (-0.71, -0.01)
-0.67 (-1.02, -0.31)
-0.70 (-1.18, -0.22)
0.11 (-0.43, 0.64)
SMD (95% CI)
-0.22 (-0.61, 0.17)
-0.10 (-0.42, 0.21)
-0.63 (-1.15, -0.11)
100.00
47.85
24.77
22.40
Weight
29.75
52.15
23.08
%
0-1.18 1.18
D
Fig. 3 (continued)
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We show that synbiotic supplementation may result in an im-
provement in FPG, insulin, HOMA-IR, HOMA-B, QUICKI,
triglycerides, total cholesterol, and VLDL-cholesterol levels,
but did not affect LDL-cholesterol and HDL-cholesterol levels
in patients with diabetes.
The hypothesis that probiotics and synbiotics may be in-
volved in the maintenance of healthy gut microbiota and the
management of glucose metabolism and lipid profiles has re-
ceived much attention. In a study by Gomes et al. [20], the
ratio of bacteroidetes species in T2DM was correlated posi-
tively with fasting plasma glucose. The alterations in gut mi-
crobiota have recently been reported in subjects with T2DM,
and this may be reversible with probiotic intake [21]. The
results of our meta-analysis revealed that synbiotic supple-
mentation significantly reduced FPG, insulin levels, HOMA-
IR, and HOMA-B and increased QUICKI score in patients
with diabetes. In a recent meta-analysis by Kasinska et al.
[22], a significant effect of probiotic supplementation on re-
ducing HbA1c levels and HOMA-IR was observed; however,
there was no effect on FPG and insulin concentrations. In
another meta-analysis study by Beserra et al. [9], synbiotic
intake in adults with overweight or obesity significantly de-
creased insulin and triglyceride levels and prebiotic
supplementation decreased total cholesterol and LDL-
cholesterol values in overall analysis, and decreased triglycer-
ides and increased HDL-cholesterol values in patients with
diabetes. In addition, a meta-analysis by Samah et al. [23]
showed that FGDwas significantly lower following consump-
tion of probiotic supplements. The findings of our meta-
analysis are in agreement with the previous review, suggesting
that a combination of probiotic species in synbiotic supple-
ments is more effective than single-species probiotics [24].
An interesting observation in the current meta-analysis was
that synbiotic supplementation was associated with improve-
ment in HOMA-IR among participants with impaired glucose
tolerance and insulin resistance at baseline, a common feature
in T2DM patients. Insulin resistance is pathogenic for several
prevalent disorders such as T2DM, CVD, polycystic ovary
syndrome, non-alcoholic fatty liver disease, and several can-
cers [25]. Accurate mechanism of synbiotic function on glu-
cose metabolism is unclear. The glucose-lowering effects of
synbiotics may be related to the reduction in oxidative stress
activities [26]. Previous studies have shown that specific
strains of lactic acid bacteria have antioxidant properties [27,
28]. For instance, Yadav et al. [29] revealed that probiotic
dahi-supplemented diet, a fermented milk containing
NOTE: Weights are from random effects analysis
Overall (I-squared = 55.7%, p = 0.080)
Subtotal (I-squared = 49.7%, p = 0.158)
ahmadi (2016)
Subtotal (I-squared = 66.5%, p = 0.084)
ID
synbiotic food
Asemi (2016)
synbiotic capsules
Tajadadi-Ebrahimi (2014)
Tajadadi-Ebrahimi (2016)
Study
0.46 (0.09, 0.82)
0.26 (-0.23, 0.75)
0.50 (0.02, 0.98)
0.66 (0.07, 1.25)
SMD (95% CI)
0.39 (0.00, 0.78)
1.00 (0.43, 1.57)
0.00 (-0.51, 0.51)
100.00
49.19
25.28
50.81
Weight
29.46
21.34
23.91
%
0-1.57 1.57
E
Fig. 3 (continued)
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Lactobacillus acidophilus and Lactobacillus casei, delayed
the progression of glucose intolerance, hyperglycemia, and
hyperinsulinemia via decreased oxidative stress in animal
models. In addition, synbiotics may have antidiabetic effects
through modulating immune responses and systemic low-
grade inflammation, in particular by reducing inflammatory
cytokines [30] and suppressing the nuclear factor kappa light
Table 3 Estimation of the standardized difference means of related indictors and confidence interval 95% before and after synbiotic consumption
between the intervention and placebo groups
Parameter Number
of study
Standardized mean
difference
95% CI Heterogeneity
I-
squared
(%)
Q P value
FPG Intervention group (after vs. before) 6 0.24 −0.69, 1.16 95.4 109.9 <0.001
Placebo group (after vs. before) 6 0.21 0.03, 0.40 0.0 4.5 0.471
Intervention group vs. placebo
group
6 −0.29 −0.47, −0.10 18.8 6.16 0.291
Insulin Intervention group (after vs. before) 5 −0.82 −1.83, 0.19 95.5 89.12 <0.001
Placebo group (after vs. before) 5 0.53 0.19, 0.86 64.2 11.17 0.025
Intervention group vs. placebo
group
5 −0.84 −1.61, −0.06 92.6 54.23 <0.001
HOMA-IR Intervention group (after vs. before) 5 −0.33 −0.53, −0.14 27.9 5.55 0.236
Placebo group (after vs. before) 5 0.58 0.07, 1.09 84.0 25.02 <0.001
Intervention group vs. placebo
group
5 −0.80 −1.58, −0.03 92.6 54.40 <0.001
HOMA-B Intervention group (after vs. before) 4 −0.20 −0.43, 0.03 1.6 3.05 0.384
Placebo group (after vs. before) 4 0.32 0.09, 0.55 0.0 1.47 0.690
Intervention group vs. placebo
group
4 −0.36 −0.71, −0.01 53.0 6.38 0.094
QUICKI Intervention group (after vs. before) 4 0.30 −0.07, 0.66 58.1 7.15 0.067
Placebo group (after vs. before) 4 −0.24 −0.48, −0.01 0.00 1.66 0.674
Intervention group vs. placebo
group
4 0.46 0.09, 0.82 55.7 6.77 0.080
Total cholesterol Intervention group (after vs. before) 6 0.36 −0.83, 1.55 96.7 151.31 <0.001
Placebo group (after vs. before) 6 0.16 −0.35, 0.66 84.0 31.26 <0.001
Intervention group vs. placebo
group
6 −0.32 −0.67, −0.03 66.4 14.87 0.011
Triglycerides Intervention group (after vs. before) 6 0.38 −0.89, 1.65 97.0 168.21 <0.001
Placebo group (after vs. before) 6 0.45 −0.07, 0.97 84.5 32.32 <0.001
Intervention group vs. placebo
group
6 −0.36 −0.55, −0.17 29.7 7.11 0.213
LDL-cholesterol Intervention group (after vs. before) 5 0.48 −0.51, 1.48 95.5 89.34 <0.001
Placebo group (after vs. before) 5 0.27 −0.25, 0.78 84.8 26.35 <0.001
Intervention group vs. placebo
group
5 −0.07 −0.58, 0.43 84.4 25.58 <0.001
HDL-cholesterol Intervention group (after vs. before) 6 0.51 −0.33, 1.34 93.9 81.70 <0.001
Placebo group (after vs. before) 6 −0.54 −0.97, −0.11 77.4 22.09 0.001
Intervention group vs. placebo
group
6 −0.25 −0.81, 0.31 87.0 38.49 <0.001
VLDL-cholesterol Intervention group (after vs. before) 4 −0.09 −0.33, 0.14 0.0 2.65 0.449
Placebo group (after vs. before) 4 0.36 0.12, 0.59 0.00 0.36 0.948
Intervention group vs. placebo
group
4 −0.31 −0.55, −0.08 44.6 5.42 0.144
Fig. 4 a–e Meta-analysis lipid profiles’ standardized mean difference
estimates for a total cholesterol, b for triglycerides, c for LDL-
cholesterol, d for HDL-cholesterol, and e for VLDL-cholesterol in
synbiotic and placebo groups (CI = 95%). FPG fasting plasma glucose,
HOMA-IR homeostasis model assessment of insulin resistance,HOMA-B
homeostatic model assessment-B cell function, QUICKI quantitative
insulin sensitivity check index
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chain enhancer of activated B cell (NF-κB) pathway [31].
Furthermore, probiotic and inulin intake may improve insulin
resistance through upregulation in the expression of peroxi-
some proliferator-activated receptor gamma (PPAR-γ) gene
[32, 33]. Wang et al. [34] found that L. casei significantly
increased the expression of PPAR-γ gene in a rat model of
acute liver failure induced by lipopolysaccharide and d-
galactosamine for 30 days. Downregulation in the expression
of hepatic genes involved in lipogenesis and fatty acid
elongation/desaturation by inulin may also result in improve-
ment in markers of insulin metabolism [35].
We found that synbiotic supplementation in patients with
diabetes significantly reduced triglycerides, total cholesterol,
and VLDL-cholesterol levels, but did not alter LDL-
cholesterol and HDL-cholesterol levels. Although several
meta-analyses studies have demonstrated that probiotic sup-
plementation is effective for the improvement of hyperlipid-
emia, the characteristics of subjects who consume probiotics
with the most beneficial effects remained unclear. In a meta-
analysis of 30 RCTs with 1624 participants by Cho et al. [36],
probiotic supplementation resulted in statistically significant
decreases in total cholesterol and LDL-cholesterol compared
to control subjects by 7.8 and 7.3 mg/dL, respectively, but did
not affect HDL-cholesterol or triglyceride concentrations. In
another meta-analysis study of 33 RCTs by Shimizu et al.
[37], probiotic interventions, including fermented milk prod-
ucts and probiotics, led to significant changes in total choles-
terol and LDL-cholesterol levels; however, it did not influence
HDL-cholesterol and triglyceride levels. However, Agerholm-
Larsen et al. [38] revealed that the duration of probiotic con-
sumption had no significant effect on total cholesterol and
LDL-cholesterol reduction using regression analysis. This dif-
ference in findings with other studies was likely due to a short
duration (4–8 weeks) of supplementation in trial conducted by
Agerholm-Larsen et al. Long-term (>4 weeks) synbiotic sup-
plementation was more effective in reduction of lipid profiles,
which could be useful in reduced risk of CVD. Synbiotic
intake may decrease triglycerides and VLDL-cholesterol
values through lipolysis of triglycerides and transform
triglyceride-rich particles into small [39], suppressing the
NF-κB pathway [31], and gut microbiota-SCFA-hormone ax-
is [40]. Several possible mechanisms proposed for the remov-
al of cholesterol from media, such as assimilation of choles-
terol during growth by L. acidophilus [41], binding of choles-
terol to the cellular surface, disruption of cholesterol micelles
[42], and deconjugation of bile salt and bile salt hydrolase
activity [41]. The meta-analysis findings regarding potential
benefit of probiotics to manage or prevent metabolic disorders
are influenced by differences in the study design, inclusion
criteria of the studies, and method for data analysis. One
E
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consideration is that the studies were conducted in many dif-
ferent geographic areas; therefore, the metabolic modifier fac-
tors, such as diet, lifestyle, and genetic background, are dif-
ferent. For example, the effectiveness of probiotic intervention
could depend on the patient’s intestinal microbiome, and this
is highly regulated by the factors, including age, diet, lifestyle,
and genetics [43]. Of these, diet is easiest to modify and pre-
sents the simplest route for therapeutic intervention. In a study
by Wu et al. [44], it observed that microbiome composition
changed detectably within 24 h of initiating a high-fat/low-
fiber or low-fat/high-fiber diet but that enterotype identity
remained stable during the 10-day study. Therefore, alterna-
tive enterotype states are related to long-term diet [44]. In
addition, functional immaturity of the immune system and
intestinal epithelium can affect the aberrant intestinal coloni-
zation pattern occurring in preterm neonates [45]. Drugs,
especially chronic medication, can exert a strong impact on
intestinal microbiota [46]. A misbalance of this intestinal mi-
crobial community can act as an important source of infection,
or inflammation, and can be involved, as well, in gastrointes-
tinal diseases and other extra-intestinal disorders. Probiotic
intervention might also be more effective when provided with
a prebiotic in a synbiotic combination, but the effectiveness of
this intervention could depend dramatically on diet or genet-
ics. We have previously shown that consumption of the
synbiotic bread compared with probiotic bread and placebo
among diabetic patients had more beneficial effects on insulin
metabolism [19]. Prior studies have reported that inclusion of
prebiotic substances like inulin can stimulate the growth and/
or metabolic activity of the selected bacterial groups including
bifidobacteria or lactobacilli and might increase production of
SCFA in the colon [47, 48]. Different probiotics might be
more beneficial when considering what the endogenous
microbiome is. The effectiveness of different types of
probiotics or prebiotics can be different in diverse populations,
as the endogenous microbiome is affected by the person’s diet
or genetic background. For instance, the consumption of pro-
biotic containing L. acidophilus and Bifidobacterium lactis in
patients with T2DM improved fasting blood glucose and an-
tioxidant status [26], whereas probiotic supplementation con-
taining L. acidophilus and B. lactis in overweight men and
women did not affect glycemic control [49]. Therefore, a spe-
cific type of probiotic might not be useful or effective for all.
Synbiotic supplementation may result in an improvement
in FPG, insulin, HOMA-IR, HOMA-B, QUICKI, triglycer-
ides, total cholesterol, and VLDL-cholesterol levels, but did
not affect LDL-cholesterol and HDL-cholesterol levels in pa-
tients with diabetes. Additional prospective studies regarding
the effect of synbiotic intake on glucose homeostasis parame-
ters and lipid profiles in patients with diabetes are necessary.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
For Studies with Human Subjects All procedures in selected papers
followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2008. Informed
consent was obtained from all patients for being included in the study.
Funding The current study was founded by a grant from the Vice
Chancellor for Research, KUMS, in Iran.
References
1. McGillicuddy FC, Roche HM (2012) Nutritional status, genetic
susceptibility, and insulin resistance—important precedents to
Table 4 Factors associated with the heterogeneity by using univariate
meta-regression model
Mean Variables B P value
FPG Strain 15.06 0.378
Time of intervention 26.12 0.042
Number of bacteria 15.06 0.378
Insulin Strain −2.37 0.041
Time of intervention −0.31 0.883
Number of bacteria −2.37 0.041
HOMA-IR Strain 0.33 0.495
Time of intervention −0.58 0.169
Number of bacteria 0.33 0.495
HOMA-B Strain −22.57 0.051
Time of intervention −3.99 0.829
Number of bacteria −22.57 0.051
QUICKI Strain −0.01 0.106
Time of intervention 0.01 0.709
Number of bacteria −0.01 0.106
Total cholesterol Strain −5.95 0.711
Time of intervention 3.35 0.845
Number of bacteria −1.41 0.935
Triglycerides Strain 2.92 0.896
Time of intervention −1.38 0.954
Number of bacteria −10.82 0.642
LDL-cholesterol Strain −1.07 0.939
Time of intervention 11.74 0.361
Number of bacteria −1.07 0.939
HDL-cholesterol Strain 0.22 0.955
Time of intervention −2.63 0.528
Number of bacteria −2.68 0.518
VLDL-cholesterol Strain 0.14 0.984
Time of intervention −3.36 0.618
Number of bacteria 0.14 0.984
340 Probiotics & Antimicro. Prot. (2018) 10:329–342
atherosclerosis. Mol Nutr Food Res 56:1173–1184. doi:10.1002/
mnfr.201100785
2. Schubert CM, Rogers NL, Remsberg KE, Sun SS, Chumlea WC,
Demerath EW, Czerwinski SA, Towne B, Siervogel RM (2006)
Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during
middle age: the Fels Longitudinal Study. Int J Obes 30:251–260
3. Moosheer SM, Waldschutz W, Itariu BK, Brath H, Stulnig TM
(2014) A protein-enriched low glycemic index diet with omega-3
polyunsaturated fatty acid supplementation exerts beneficial effects
on metabolic control in type 2 diabetes. Prim Care Diabetes 8:308–
314. doi:10.1016/j.pcd.2014.02.004
4. Asemi Z, Hashemi T, Karamali M, Samimi M, Esmaillzadeh A
(2013) Effects of vitamin D supplementation on glucose metabo-
lism, lipid concentrations, inflammation, and oxidative stress in
gestational diabetes: a double-blind randomized controlled clinical
trial. Am J Clin Nutr 98:1425–1432. doi:10.3945/ajcn.113.072785
5. Gao D, Ning N, Wang C, Wang Y, Li Q, Meng Z, Liu Y, Li Q
(2013) Dairy products consumption and risk of type 2 diabetes:
systematic review and dose-response meta-analysis. PLoS One 8:
e73965. doi:10.1371/journal.pone.0073965
6. de Vrese M, Schrezenmeir J (2008) Probiotics, prebiotics, and
synbiotics. Adv Biochem Eng Biotechnol 111:1–66. doi:10.1007/
10_2008_097
7. Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil
A (2016) Effects of Probiotics and Synbiotics on Obesity, Insulin
Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty
Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci
:17(6). doi:10.3390/ijms17060928.
8. Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N,
Ghandi Y, Asemi Z (2014) Consumption of synbiotic bread de-
creases triacylglycerol and VLDL levels while increasing HDL
levels in serum from patients with type-2 diabetes. Lipids 49:695–
701. doi:10.1007/s11745-014-3901-z
9. Beserra BT, Fernandes R, do Rosario VA, Mocellin MC, Kuntz
MG, Trindade EB (2015) A systematic review and meta-analysis
of the prebiotics and synbiotics effects on glycaemia, insulin con-
centrations and lipid parameters in adult patients with overweight or
obesity. Clin Nutr 34:845–858. doi:10.1016/j.clnu.2014.10.004
10. Ruan Y, Sun J, He J, Chen F, Chen R, Chen H (2015) Effect of
probiotics on glycemic control: a systematic review and meta-
analysis of randomized, controlled trials. PLoS One 10:e0132121.
doi:10.1371/journal.pone.0132121
11. Vitali B, Ndagijimana M, Maccaferri S, Biagi E, Guerzoni ME,
Brigidi P (2012) An in vitro evaluation of the effect of probiotics
and prebiotics on the metabolic profile of human microbiota.
Anaerobe 18:386–391. doi:10.1016/j.anaerobe.2012.04.014
12. Voltolini C, Battersby S, Etherington SL, Petraglia F, Norman JE,
Jabbour HN (2012) A novel antiinflammatory role for the short-
chain fatty acids in human labor. Endocrinology 153:395–403. doi:
10.1210/en.2011-1457
13. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R,
Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F,
Respondek F, Whelan K, Coxam V, Davicco MJ, Léotoing L,
Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A
(2010) Prebiotic effects: metabolic and health benefits. Br J Nutr
104(Suppl 2):S1–S6. doi:10.1017/S0007114510003363
14. Ahmadi S, Jamilian M, Tajabadi-Ebrahimi M, Jafari P, Asemi Z
(2016) The effects of synbiotic supplementation on markers of in-
sulin metabolism and lipid profiles in gestational diabetes: a
randomised, double-blind, placebo-controlled trial. Br J Nutr 116:
1394–1401. doi:10.1017/S0007114516003457
15. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh
A (2014) Effects of synbiotic food consumption onmetabolic status
of diabetic patients: a double-blind randomized cross-over con-
trolled clinical trial. Clin Nutr 33:198–203. doi:10.1016/j.clnu.
2013.05.015
16. Asemi Z, Alizadeh SA, Ahmad K, Goli M, Esmaillzadeh A (2016)
Effects of beta-carotene fortified synbiotic food on metabolic con-
trol of patients with type 2 diabetes mellitus: a double-blind ran-
domized cross-over controlled clinical trial. Clin Nutr 35:819–825.
doi:10.1016/j.clnu.2015.07.009
17. Moroti C, Souza Magri LF, de Rezende CM, Cavallini DC, Sivieri
K (2012) Effect of the consumption of a new symbiotic shake on
glycemia and cholesterol levels in elderly people with type 2 dia-
betes mellitus. Lipids Health Dis 11:29. doi:10.1186/1476-511X-
11-29
18. Tajabadi-EbrahimiM, Sharifi N, FarrokhianA, Raygan F, Karamali
F, Razzaghi R, Taheri S, Asemi Z (2017) A randomized controlled
clinical trial investigating the effect of synbiotic administration on
markers of insulin metabolism and lipid profiles in overweight type
2 diabetic patients with coronary heart disease. Exp Clin Endocrinol
Diabetes 125:21–27. doi:10.1055/s-0042-105441
19. Tajadadi-EbrahimiM, Bahmani F, Shakeri H, HadaeghH, Hijijafari
M, Abedi F, Asemi Z (2014) Effects of daily consumption of
synbiotic bread on insulin metabolism and serum high-sensitivity
C-reactive protein among diabetic patients: a double-blind, random-
ized, controlled clinical trial. Ann Nutr Metab 65:34–41. doi:10.
1159/000365153
20. Gomes AC, Bueno AA, de Souza RG, Mota JF (2014) Gut micro-
biota, probiotics and diabetes. Nutr J 13:60. doi:10.1186/1475-
2891-13-60
21. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen
AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH,
Jakobsen M (2010) Gut microbiota in human adults with type 2
diabetes differs from non-diabetic adults. PLoS One 5:e9085. doi:
10.1371/journal.pone.0009085
22. Kasinska MA, Drzewoski J (2015) Effectiveness of probiotics in
type 2 diabetes: a meta-analysis. Pol Arch Med Wewn 125:803–
813. doi:10.20452/pamw.3156
23. Samah S, Ramasamy K, Lim SM, Neoh CF (2016) Probiotics for
the management of type 2 diabetes mellitus: a systematic review
and meta-analysis. Diabetes Res Clin Pract 118:172–182. doi:10.
1016/j.diabres.2016.06.014
24. Chapman CM, Gibson GR, Rowland I (2011) Health benefits of
probiotics: are mixtures more effective than single strains? Eur J
Nutr 50:1–17. doi:10.1007/s00394-010-0166-z
25. Prudente S, Trischitta V (2015) The TRIB3 Q84R polymorphism,
insulin resistance and related metabolic alterations. Biochem Soc
Trans 43:1108–1111. doi:10.1042/BST20150115
26. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M,
Asghari-Jafarabadi M, Mofid V (2012) Probiotic yogurt improves
antioxidant status in type 2 diabetic patients. Nutrition 28:539–543.
doi:10.1016/j.nut.2011.08.013
27. Amaretti A, di Nunzio M, Pompei A, Raimondi S, Rossi M,
Bordoni A (2013) Antioxidant properties of potentially probiotic
bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol
97:809–817. doi:10.1007/s00253-012-4241-7
28. Uskova MA, Kravchenko LV (2009) Antioxidant properties of lac-
tic acid bacteria—probiotic and yogurt strains. Vopr Pitan 78:18–23
29. Yadav H, Jain S, Sinha PR (2007) Antidiabetic effect of probiotic
dahi containing Lactobacillus acidophilus and Lactobacillus casei
in high fructose fed rats. Nutrition 23:62–68
30. de Moreno de Leblanc A, Perdigon G (2010) The application of
probiotic fermented milks in cancer and intestinal inflammation.
Proc Nutr Soc 69:421–428. doi:10.1017/S002966511000159X
31. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006)
TLR4 links innate immunity and fatty acid-induced insulin resis-
tance. J Clin Invest 116:3015–3025
32. Deepak V, Ram Kumar Pandian S, Sivasubramaniam SD, Nellaiah
H, Sundar K (2016) Optimization of anticancer exopolysaccharide
production from probiotic Lactobacillus acidophilus by response
Probiotics & Antimicro. Prot. (2018) 10:329–342 341
surface methodology. Prep Biochem Biotechnol 46:288–297. doi:
10.1080/10826068.2015.1031386
33. Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Van Holle A,
Muccioli GG, Deldicque L, Bindels LB, Pachikian BD, Sohet FM,
Mignolet E, Francaux M, Larondelle Y, Delzenne NM (2011)
Inulin-type fructans with prebiotic properties counteract GPR43
overexpression and PPARgamma-related adipogenesis in the white
adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22:712–
722. doi:10.1016/j.jnutbio.2010.05.009
34. Wang Y, Xie J, Li Y, Dong S, Liu H, Chen J, Wang Y, Zhao S,
Zhang Y, Zhang H (2016) Probiotic Lactobacillus casei Zhang re-
duces pro-inflammatory cytokine production and hepatic inflamma-
tion in a rat model of acute liver failure. Eur J Nutr 55:821–831. doi:
10.1007/s00394-015-0904-3
35. Weitkunat K, Schumann S, Petzke KJ, Blaut M, Loh G, Klaus S
(2015) Effects of dietary inulin on bacterial growth, short-chain
fatty acid production and hepatic lipid metabolism in gnotobiotic
mice. J Nutr Biochem 26:929–937. doi:10.1016/j.jnutbio.2015.03.
010
36. Cho YA, Kim J (2015) Effect of probiotics on blood lipid concen-
trations: a meta-analysis of randomized controlled trials. Medicine
(Baltimore) 94:e1714. doi:10.1097/MD.0000000000001714
37. Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M
(2015) Meta-analysis: effects of probiotic supplementation on lipid
profiles in normal to mildly hypercholesterolemic individuals.
PLoS One 10:e0139795. doi:10.1371/journal.pone.0139795
38. Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A (2000) The
effect of a probiotic milk product on plasma cholesterol: a meta-
analysis of short-term intervention studies. Eur J Clin Nutr 54:856–
860
39. Matsuoka H, Miura A, Hori K (2009) Symbiotic effects of a lipase-
secreting bacterium, Burkholderia arboris SL1B1, and a glycerol-
assimilating yeast, Candida cylindracea SL1B2, on triacylglycerol
degradation. J Biosci Bioeng 107:401–408. doi:10.1016/j.jbiosc.
2008
40. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG (2013) Beneficial
metabolic effects of a probiotic via butyrate-induced GLP-1 hor-
mone secretion. J Biol Chem 288:25088–25097. doi:10.1074/jbc.
M113.452516
41. Klaver FA, van der Meer R (1993) The assumed assimilation of
cholesterol by Lactobacilli and Bifidobacterium bifidum is due to
their bile salt-deconjugating activity. Appl Environ Microbiol 59:
1120–1124
42. Lye H-S, Rahmat-Ali GR, Liong M-T (2010) Mechanisms of cho-
lesterol removal by lactobacilli under conditions that mimic the
human gastrointestinal tract. Int Dairy J 20:169–175. doi:10.1016/
j.idairyj.2009.10.003
43. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel
BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE (2006)
Metagenomic analysis of the human distal gut microbiome. Science
312:1355–1359
44. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh
SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy
E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD
(2011) Linking long-term dietary patterns with gut microbial
enterotypes. Science 334:105–108. doi:10.1126/science.1208344
45. Arboleya S, Ang L, Margolles A, Yiyuan L, Dongya Z, Liang X,
Solís G, Fernández N, de Los Reyes-Gavilán CG, Gueimonde M
(2012) Deep 16S rRNA metagenomics and quantitative PCR anal-
yses of the premature infant fecal microbiota. Anaerobe 18:378–
380. doi:10.1016/j.anaerobe.2012.04.013
46. Perez-Cobas AE, Artacho A, Knecht H, Ferrús ML, Friedrichs A,
Ott SJ, Moya A, Latorre A, Gosalbes MJ (2013) Differential effects
of antibiotic therapy on the structure and function of human gut
microbiota. PLoS One 8:e80201. doi:10.1371/journal.pone.
0080201
47. Gibson GR, Roberfroid MB (1995) Dietary modulation of the hu-
man colonic microbiota: introducing the concept of prebiotics. J
Nutr 125:1401–1412
48. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB
(2004) Dietary modulation of the human colonic microbiota:
updating the concept of prebiotics. Nutr Res Rev 17:259–275
49. Ivey KL, Hodgson JM, Kerr DA, Lewis JR, Thompson PL, Prince
RL (2014) The effects of probiotic bacteria on glycaemic control in
overweight men and women: a randomised controlled trial. Eur J
Clin Nutr 68:447–452. doi:10.1038/ejcn.2013.294
342 Probiotics & Antimicro. Prot. (2018) 10:329–342
